First self-administered, targeted B-cell therapy licensed for adults with relapsing forms of MS
News
UK government launches search for at-home COVID-19 treatments
Antivirals Taskforce established in a bid to identify promising at-home antiviral medicines
Real-world data suggests Sputnik V vaccine is 97.6% effective, says RDIF
Data comes from 3.8 million Russians vaccinated with COVID-19 vaccine
Breakthrough designation granted for Amgen’s bemarituzumab
Amgen gained access to bemarituzumab as part of its acquisition of Five Prime Therapeutics
Enhertu accepted via cancer drugs fund for HER2-positive breast cancer
Decision is based on results from the Phase II DESTINY-Breast01 trial
NICE’s five-year strategy sets a ‘positive vision for the future’
Pharma and diagnostic sectors respond to organisation’s latest guideline recommendations
NICE unveils new strategy to improve patient access to innovative treatments
Five-year strategy will seek to transform key elements of organisation’s approach to latest treatments
Phico Therapeutics gains £13.1m grant to advance antibacterial therapy
SASPject PT3.9 is designed for the treatment of hospital infections caused by Pseudomonas aeruginosa
New advice on COVID-19 vaccination for pregnant women in UK
JCVI advises pregnant women in the UK be offered COVID-19 vaccination at the same time as the rest of the population
TG Therapeutics’ ublituximab tops Sanofi’s Aubagio in MS trial
Ublituximab significantly reduced the annualised relapse rate in patients with relapsing forms of multiple sclerosis
EC approves new Sarclisa indication
Sarclisa has been approved in combination with a standard of care regimen for relapsed multiple myeloma
New subcutaneous formulation of Tysabri approved in UK
Multiple sclerosis treatment can now be administered subcutaneously or intravenously
EMA begins review of GSK/Vir’s COVID-19 antibody
The review will include an interim analysis of efficacy and safety data from the Phase III COMET-ICE trial
Roche’s SMA treatment Evrysdi demonstrates continued improvements in infants
Drug continuously improved motor function and survival in babies after 24 months of treatment
NICE recommends Alexion’s PNH treatment Ultomiris
C5 complement inhibitor approved to treat PNH in adult patients with haemolysis
